Search Results
News Releases
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from MSD Animal Health
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly1 injectable product to treat and protect dogs from fleas and ticks.
Featured Stories
Big data can carry farming forward. Now more than ever, farmers must embrace it.
To most Americans, farmers remain unseen figures behind the food on their dinner tables — hand-written records, calloused hands, and long days of physical labor.
News Releases
MSD Animal Health Receives Positive Opinion from CVMP for NOBIVAC® L6 and NOBIVAC® LoVo L6 Vaccines for Use in Dogs Against Leptospirosis
Today we announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines for use against leptospirosis in dogs.
News Releases
MSD Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – MSD Animal Health
News Releases
MSD Animal Health Receives Positive CVMP Opinion for INNOVAX®-ND-IBD-ILT for Use in Chickens
MSD Animal Health to Showcase Innovations in Ruminant Health at the World Buiatrics Congress in Cancun, Mexico.
News Releases
MSD Animal Health Demonstrates its Commitment to Ruminant Health at the 2025 European Buiatrics Congress
Presenting more than 10 new studies and continuing to solve unmet medical needs in the Ruminant space. Join us at EBC 2025 in France.
News Releases
FDA Approves MSD Animal Health’s MOMETAMAX SINGLE™ to Treat Otitis Externa in Dogs
The leading manufacturer of otic treatments expands portfolio with the only FDA-approved, one dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens RAHWAY, N.J., May 02, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced
News Releases
MSD Animal Health Announces the European Approval of NOBILIS MULTRIVA™ REOm for Use in Chickens
NOBILIS MULTRIVA™ REOm, a new vaccine to help reduce viraemia and clinical signs of disease caused by avian reovirus, expanding NOBILIS MULTRIVA portfolio.
Featured Stories
Evolving Customer Relationships With Subscriptions
Subscription-based business models are changing industries from movies to media to software, and they’re altering animal health, too.
News Releases
MSD Animal Health Announces New Agreement with Union Agener Animal Health for Worldwide Distributorship of LACTOTROPIN®
Today we announce our new agreement with Union Agener Animal Health for Worldwide Distributorship of LACTOTROPIN®.
News Releases
MSD Animal Health Wins 2024 S&P Global Award for Best New Companion Animal Product for injectable formulation of BRAVECTO® (fluralaner)
BRAVECTO® (fluralaner) injectable formulation awarded for best new companion animal product by S&P Global.
News Releases
MSD Animal Health and Veterinarians of Europe (FVE) Reward 34 Veterinary Students from across Europe for Scholarship Program
34 Veterinary students from across Europe awarded the 2024 Veterinary Scholarship Program